1,824
Views
18
CrossRef citations to date
0
Altmetric
Report

Characterization of a quantitative method to measure free proprotein convertase subtilisin/kexin type 9 in human serum

, , , , &
Pages 1103-1113 | Received 24 Feb 2014, Accepted 31 Mar 2014, Published online: 16 Apr 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Chao Liu, Hong Lu, Fei Yuan, Wei-Li Chen, Hong-Rong Xu, Hui Li, Cheng-Pang Hsu, Ogo Egbuna, Jihua Wu, Clapton Dias, Bassam Abosaleem, Jitesh Rana, Maria Laura Monsalvo, Xue-Ning Li & Zhigang Yu. (2019) A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects. Clinical Pharmacology: Advances and Applications 11, pages 145-153.
Read now

Articles from other publishers (17)

Yan G. Ni, Lindsay E. King & Carmen Fernández‐Metzler. 2022. Bioanalytical Aspects in Biological Therapeutics. Bioanalytical Aspects in Biological Therapeutics 87 140 .
Jihua Chen, Kimberly Kendra, Stacey Shank, Ashique Rafique, George Ehrlich, Kuan-Ju Lin, Lisa DeStefano, Matthew D Andisik, Michael A Partridge, Albert Torri & Giane Sumner. (2022) Assay pH and critical reagent optimization in measuring concentrations of a monoclonal antibody and its target. Bioanalysis 14:8, pages 491-502.
Crossref
Tanawan Kongmalai, Nalinee Chuanchaiyakul, Chattip Sripatumtong, Tunsuda Tansit, Yuttana Srinoulprasert, Nareerak Klinsukon & Nuntakorn Thongtang. (2021) The effect of temperature on the stability of PCSK-9 monoclonal antibody: an experimental study. Lipids in Health and Disease 20:1.
Crossref
Georgios Louloudis, Samuele Ambrosini, Francesco Paneni, Giovanni G. Camici, Dietmar Benke & Jan Klohs. (2021) Adeno-Associated Virus-Mediated Gain-of-Function mPCSK9 Expression in the Mouse Induces Hypercholesterolemia, Monocytosis, Neutrophilia, and a Hypercoagulative State. Frontiers in Cardiovascular Medicine 8.
Crossref
Yun Liu, Ronald Robinson, Thao Ung, Chrysanthe Spais, Justin Schreiber, Jacquelyn Lyons, Jean Husten, Hussein Hallak & Thelma Angeles. (2021) Development of a Meso Scale Discovery ligand-binding assay for measurement of free (drug-unbound) target in nonhuman primate serum. Bioanalysis 13:7, pages 575-585.
Crossref
Edward Lee, John P. Gibbs, Maurice G. Emery, Geoffrey Block, Scott M. Wasserman, Lisa Hamilton, Sreeneeranj Kasichayanula, Patrick Hanafin, Ransi Somaratne & Ogo Egbuna. (2019) Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety. Clinical Pharmacology in Drug Development 8:3, pages 281-289.
Crossref
Meric Ovacik & Kedan Lin. (2018) Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development. Clinical and Translational Science 11:6, pages 540-552.
Crossref
Scott M. Wasserman, Marc S. Sabatine, Michael J. Koren, Robert P. Giugliano, Jason C. Legg, Maurice G. Emery, Sameer Doshi, Thomas Liu, Ransi Somaratne & John P. Gibbs. (2018) Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals. Journal of Cardiovascular Pharmacology and Therapeutics 23:5, pages 423-432.
Crossref
Sreeneeranj Kasichayanula, Anita Grover, Maurice G. Emery, Megan A. Gibbs, Ransi Somaratne, Scott M. Wasserman & John P. Gibbs. (2018) Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clinical Pharmacokinetics 57:7, pages 769-779.
Crossref
John P. Gibbs, Sameer Doshi, Mita Kuchimanchi, Anita Grover, Maurice G. Emery, Michael G. Dodds, Megan A. Gibbs, Ransi Somaratne, Scott M. Wasserman & Dirk Blom. (2016) Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). The Journal of Clinical Pharmacology 57:5, pages 616-626.
Crossref
John P. Gibbs, J. Greg Slatter, Ogo Egbuna, Michelle Geller, Lisa Hamilton, Clapton S. Dias, Ren Y. Xu, Jessica Johnson, Scott M. Wasserman & Maurice G. Emery. (2017) Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment. The Journal of Clinical Pharmacology 57:4, pages 513-523.
Crossref
Gerald F. WattsDick C. ChanRicardo DentRansi SomaratneScott M. WassermanRob ScottSally BurrowsP. Hugh R. Barrett. (2017) Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism. Circulation 135:4, pages 338-351.
Crossref
Fang Xie, Maurice G Emery, John P Gibbs, Dan A Rock & Brooke M Rock. (2016) SRM-based measurements of proprotein convertase subtilisin/kexin type 9 and lipoprotein(a) kinetics in nonhuman primate serum. Bioanalysis 8:24, pages 2551-2563.
Crossref
Macarena Fritz Kelly. (2016) Antibody Validation. Materials and Methods 6.
Crossref
Teik Chye Ooi & Hussein Abujrad. 2016. Biomarkers in Cardiovascular Disease. Biomarkers in Cardiovascular Disease 125 151 .
Xuemei Zhao, Vijay Modur, Leonidas N Carayannopoulos & Omar F Laterza. (2015) Biomarkers in Pharmaceutical Research. Clinical Chemistry 61:11, pages 1343-1353.
Crossref
Teik Chye Ooi & Hussein Abujrad. 2015. Biomarkers in Cardiovascular Disease. Biomarkers in Cardiovascular Disease 1 27 .